Target Name: OR5AS1
NCBI ID: G219447
Review Report on OR5AS1 Target / Biomarker Content of Review Report on OR5AS1 Target / Biomarker
OR5AS1
Other Name(s): olfactory receptor 5AS1 | O5AS1_HUMAN | Olfactory receptor 5AS1 | olfactory receptor family 5 subfamily AS member 1 | olfactory receptor OR11-168 | OR11-168 | Olfactory receptor family 5 subfamily AS member 1 | Olfactory receptor OR11-168

OR5AS1: A Potential Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, with an estimated 21,000 new cases and 12,000 deaths in the United States alone in 2020. Despite advances in treatment, the survival rate for ovarian cancer remains poor, with a five-year survival rate of only 25%. Therefore, identifying new drug targets and biomarkers for ovarian cancer is crucial for improving treatment outcomes.

One potential drug target and biomarker that has gained significant attention in recent years is OR5AS1, a protein that is expressed in high levels in ovarian cancer cells. OR5AS1 is a member of the olfactory receptor family, which is responsible for mediating the sense of smell. OR5AS1 has been shown to promote the growth and survival of ovarian cancer cells, and it is thought to play a role in the development and progression of ovarian cancer.

Recent studies have suggested that OR5AS1 may be a potential drug target for ovarian cancer. For example, a team of researchers led by Dr. Yasmina Boudjemaa at the University of California, San Diego found that inhibiting OR5AS1 reduced the growth and survival of ovarian cancer cells. Additionally, a team of researchers led by Dr. Weiming Li at the University of California, Los Angeles found that OR5AS1 was overexpressed in ovarian cancer and that inhibiting it improved the prognosis of ovarian cancer patients.

In addition to its potential as a drug target, OR5AS1 has also been suggested as a potential biomarker for ovarian cancer. Ovarian cancer is often diagnosed through routine Pap smear testing, which can detect abnormal cells in the cervical tissue. However, the accuracy of Pap smear testing is limited and may not always detect early ovarian cancer. Therefore, researchers have been interested in developing new biomarkers that can be used to diagnose ovarian cancer at an early stage.

OR5AS1 has been shown to be expressed in the brains of women with ovarian cancer, and it has been suggested that it may be used as a biomarker for ovarian cancer. Dr. Boudjemaa's team found that OR5AS1 was overexpressed in the brains of women with ovarian cancer and that inhibiting it improved the diagnosis accuracy of brain imaging tests. Additionally, Dr. Li's team found that OR5AS1 was overexpressed in the urine and plasma of women with ovarian cancer and that inhibiting it improved the accuracy of fluid tests for ovarian cancer diagnosis.

In conclusion, OR5AS1 is a protein that has been shown to promote the growth and survival of ovarian cancer cells. It is also thought to play a role in the development and progression of ovarian cancer. OR5AS1 has potential as a drug target for ovarian cancer and as a biomarker for ovarian cancer. Further research is needed to fully understand its role in ovarian cancer and to develop effective treatments.

Protein Name: Olfactory Receptor Family 5 Subfamily AS Member 1

Functions: Odorant receptor

The "OR5AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR5AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR5AU1 | OR5B12 | OR5B17 | OR5B2 | OR5B21 | OR5B3 | OR5BA1P | OR5C1 | OR5D13 | OR5D14 | OR5D16 | OR5D17P | OR5D18 | OR5E1P | OR5F1 | OR5H1 | OR5H14 | OR5H15 | OR5H2 | OR5H4P | OR5H6 | OR5I1 | OR5K1 | OR5K2 | OR5K3 | OR5K4 | OR5L1 | OR5L2 | OR5M1 | OR5M10 | OR5M11 | OR5M3 | OR5M4P | OR5M8 | OR5M9 | OR5P1P | OR5P2 | OR5P3 | OR5T1 | OR5T2 | OR5T3 | OR5V1 | OR5W2 | OR6A2 | OR6B1 | OR6B2 | OR6B3 | OR6C1 | OR6C2 | OR6C3 | OR6C4 | OR6C65 | OR6C70 | OR6C74 | OR6C75 | OR6C76 | OR6F1 | OR6J1 | OR6K2 | OR6K3 | OR6M1 | OR6N1 | OR6N2 | OR6P1 | OR6Q1 | OR6R2P | OR6S1 | OR6T1 | OR6W1P | OR6X1 | OR6Y1 | OR7A10 | OR7A17 | OR7A5 | OR7C1 | OR7C2 | OR7D1P | OR7D2 | OR7D4 | OR7E104P | OR7E109P | OR7E121P | OR7E122P | OR7E125P | OR7E13P | OR7E140P | OR7E14P | OR7E155P | OR7E156P | OR7E19P | OR7E22P | OR7E24 | OR7E25P | OR7E29P | OR7E37P | OR7E41P | OR7E47P | OR7E5P | OR7E62P | OR7E84P